bretisilocin (GM-2505) / Gilgamesh Pharma, AbbVie - LARVOL DELTA

Pharmacokinetic, pharmacodynamic and subjective and effects of the novel 5-HT2A receptor agonist GM-2505 in healthy volunteers (ECNP 2024) - "Both objective (resting state EEG, blood pressure, neurohormones) and robust subjective (TEAEs, 5D-ASC, MEQ-30) effects were consistent with expected dose-dependent effects of psychedelic 5-HT2A receptor agonists. In Conclusion , doses with clear psychedelic effects were identified that are being evaluated in the currently ongoing Phase 2a trial in patients with major depressive disorder."

Clinical • PK/PD data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

GM-2505-201: A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Gilgamesh Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

GM-2505-201: A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Gilgamesh Pharmaceuticals

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry